share_log

SciSparc | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

SciSparc | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

SciSparc | 425：募資說明/企業合併公告
美股SEC公告 ·  2024/09/11 21:31

Moomoo AI 已提取核心訊息

On September 5, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, amended its bridge loan agreement with AutoMax Motors Ltd., providing an additional $1.85 million loan. This amendment brings the total loan amount to $4.25 million. The loan is secured by a first-ranking fixed charge on shares of AutoMax's subsidiary, AutoMax Leasing Ltd. The amendment is part of a broader agreement that includes a merger plan between SciSparc and AutoMax, initially dated April 10, 2024. Due to the loan, the previously agreed closing financing from SciSparc to AutoMax will no longer occur. AutoMax, through AutoMax Leasing, has also entered into a direct import agreement with JAC Motors, a major Chinese vehicle manufacturer. SciSparc focuses on developing treatments for central nervous system disorders and rare diseases and has several drug development programs underway. The company plans to file a registration statement and a proxy statement with the SEC in connection with the proposed transactions, and advises investors and shareholders to read these documents once available.
On September 5, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, amended its bridge loan agreement with AutoMax Motors Ltd., providing an additional $1.85 million loan. This amendment brings the total loan amount to $4.25 million. The loan is secured by a first-ranking fixed charge on shares of AutoMax's subsidiary, AutoMax Leasing Ltd. The amendment is part of a broader agreement that includes a merger plan between SciSparc and AutoMax, initially dated April 10, 2024. Due to the loan, the previously agreed closing financing from SciSparc to AutoMax will no longer occur. AutoMax, through AutoMax Leasing, has also entered into a direct import agreement with JAC Motors, a major Chinese vehicle manufacturer. SciSparc focuses on developing treatments for central nervous system disorders and rare diseases and has several drug development programs underway. The company plans to file a registration statement and a proxy statement with the SEC in connection with the proposed transactions, and advises investors and shareholders to read these documents once available.
2024年9月5日，臨床階段藥品公司SciSparc Ltd.修訂了與AutoMax Motors Ltd.的橋式貸款協議，提供額外185萬美元的貸款。此修訂將總貸款金額提高到425萬美元。該貸款以AutoMax子公司AutoMax Leasing Ltd.的股份設定的優先固定抵押品擔保。該修訂是更廣泛協議的一部分，其中包括SciSparc和AutoMax之間的併購計劃，最初日期爲2024年4月10日。由於貸款，SciSparc原先同意向AutoMax提供的收購融資將不再發生。通過AutoMax Leasing，AutoMax還與中國主要汽車製造商吉利汽車簽訂了直接進口協議。SciSparc專注於治療中樞神經系統疾病和罕見疾病，並且已有多個藥物開發項目正在進行中。該公司計劃在與擬議交易相關的註冊聲明和代理聲明上向證券交易委員會提交申請，並建議投資者和股東一旦可獲得這些文件就閱讀。
2024年9月5日，臨床階段藥品公司SciSparc Ltd.修訂了與AutoMax Motors Ltd.的橋式貸款協議，提供額外185萬美元的貸款。此修訂將總貸款金額提高到425萬美元。該貸款以AutoMax子公司AutoMax Leasing Ltd.的股份設定的優先固定抵押品擔保。該修訂是更廣泛協議的一部分，其中包括SciSparc和AutoMax之間的併購計劃，最初日期爲2024年4月10日。由於貸款，SciSparc原先同意向AutoMax提供的收購融資將不再發生。通過AutoMax Leasing，AutoMax還與中國主要汽車製造商吉利汽車簽訂了直接進口協議。SciSparc專注於治療中樞神經系統疾病和罕見疾病，並且已有多個藥物開發項目正在進行中。該公司計劃在與擬議交易相關的註冊聲明和代理聲明上向證券交易委員會提交申請，並建議投資者和股東一旦可獲得這些文件就閱讀。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！